48 regularly used medicines were recognised by the Central Drugs Standard Control Organisation (CDSCO) as having failed the most recent drug safety alert that the drug regulator issued in March.
The drug regulator has highlighted the drugs failing the quality criteria in the month of March out of the total 1,497 samples in its monthly list, which was published on its website. 1449 samples were designated as being of Standard Quality, according the list.
Anti-diabetic, antibiotic, calcium, and cardiac medications are among the drugs that come with a warning label. The list also includes some of the more well-known drugs, such as the anti-hypertension drug Telmisartan, the anti-diabetes drug combination of Glimepiride and Metformin, and the HIV drug Ritonavir.
Probiotics, various multivitamin pills, iron and folic acid tablets, and others are also on the alert list. Injections of vitamin C, vitamin B12, folic acid, and niacinamide are also included.
As well as these frequent drugs, the list also includes Amoxycillin, Calcium & Vitamin D3 Tablets, Telmisartan Tablets, and Albendazole Tablets.
After learning of this development, a Glenmark spokesperson told Financial Express.com: “We have looked into the matter and determined that the TELMA AM Tablets (Telmisartan 40 mg and Amlodipine 5 mg Tablets IP) batch number 18220076 from the NSQ list of “March 2023 Month Drugs Alert” are counterfeit drugs and were not produced by Glenmark. We have appealed for the product to be taken off the drug alert list and asked the CDSCO to take action in this regard.
The representative added that the appropriate steps had been taken.
“As a responsible manufacturer, we have occasionally given all concerned regulatory officials proactive information and leads.” The statement continued, “We have also taken the required steps, including hiring a third party organisation to look into the availability of fake pharmaceuticals across the nation.
Abott India Limited, in the meantime, published a notification informing the public that the company has voluntarily recalled one batch of Thyronorm Tablets (Thyroxine Sodium). The recalled batch is identified in the public notice as AEJ0713; Mfg., Date: March 2023. The medicine is used to treat hypothyrodism. This batch has only been billed in Madhya Pradesh and Telangana, the company claims.
Also Read: TCS onboards 44,000 freshers in FY23, honors all job offers
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK
